PRMT6 activates cyclin D1 expression in conjunction with the transcription factor LEF1.


Journal

Oncogenesis
ISSN: 2157-9024
Titre abrégé: Oncogenesis
Pays: United States
ID NLM: 101580004

Informations de publication

Date de publication:
17 May 2021
Historique:
received: 26 11 2020
accepted: 28 04 2021
revised: 15 04 2021
entrez: 18 5 2021
pubmed: 19 5 2021
medline: 19 5 2021
Statut: epublish

Résumé

The establishment of cell type specific gene expression by transcription factors and their epigenetic cofactors is central for cell fate decisions. Protein arginine methyltransferase 6 (PRMT6) is an epigenetic regulator of gene expression mainly through methylating arginines at histone H3. This way it influences cellular differentiation and proliferation. PRMT6 lacks DNA-binding capability but is recruited by transcription factors to regulate gene expression. However, currently only a limited number of transcription factors have been identified, which facilitate recruitment of PRMT6 to key cell cycle related target genes. Here, we show that LEF1 contributes to the recruitment of PRMT6 to the central cell cycle regulator CCND1 (Cyclin D1). We identified LEF1 as an interaction partner of PRMT6. Knockdown of LEF1 or PRMT6 reduces CCND1 expression. This is in line with our observation that knockdown of PRMT6 increases the number of cells in G1 phase of the cell cycle and decreases proliferation. These results improve the understanding of PRMT6 activity in cell cycle regulation. We expect that these insights will foster the rational development and usage of specific PRMT6 inhibitors for cancer therapy.

Identifiants

pubmed: 34001852
doi: 10.1038/s41389-021-00332-z
pii: 10.1038/s41389-021-00332-z
pmc: PMC8129428
doi:

Types de publication

Journal Article

Langues

eng

Pagination

42

Subventions

Organisme : Wilhelm Sander-Stiftung (Wilhelm Sander Foundation)
ID : 2018.038.1

Références

Nat Med. 2006 Oct;12(10):1191-7
pubmed: 17063141
Neuron. 2015 Jan 7;85(1):88-100
pubmed: 25569348
Cell Death Differ. 2016 May;23(5):865-75
pubmed: 26794446
Nucleic Acids Res. 2019 Jan 8;47(D1):D442-D450
pubmed: 30395289
Oncogene. 2013 May 16;32(20):2565-75
pubmed: 22777353
Nucleic Acids Res. 2014 Jul;42(13):8297-309
pubmed: 24939901
Oncotarget. 2015 Oct 13;6(31):30957-67
pubmed: 26436589
Cell Rep. 2017 Dec 19;21(12):3390-3397
pubmed: 29262320
Nat Commun. 2014 May 29;5:3995
pubmed: 24874575
Proc Natl Acad Sci U S A. 2019 Apr 2;116(14):6868-6877
pubmed: 30886105
Nat Commun. 2016 Feb 26;7:10751
pubmed: 26916619
J Biol Chem. 2008 Feb 8;283(6):3006-3010
pubmed: 18077460
Nucleic Acids Res. 2012 Oct;40(19):9513-21
pubmed: 22904064
Methods Mol Biol. 2013;1067:105-24
pubmed: 23975789
Protein Sci. 2010 Nov;19(11):2141-51
pubmed: 20812326
Proc Natl Acad Sci U S A. 1998 Sep 29;95(20):11590-5
pubmed: 9751710
Stem Cells Dev. 2012 Sep 20;21(14):2613-22
pubmed: 22455726
Mol Med Rep. 2020 Oct;22(4):3161-3172
pubmed: 32945431
Nucleic Acids Res. 2012 Oct;40(19):9534-42
pubmed: 22987071
Nature. 2007 Oct 18;449(7164):928-32
pubmed: 17898715
Int J Mol Med. 2019 Jun;43(6):2462-2470
pubmed: 30942395
Proc Natl Acad Sci U S A. 1999 May 11;96(10):5522-7
pubmed: 10318916
Mol Cell. 2017 Jan 5;65(1):8-24
pubmed: 28061334
Nature. 2007 Oct 18;449(7164):933-7
pubmed: 17898714
Nucleic Acids Res. 2012 Oct;40(19):9522-33
pubmed: 22904088
Cell. 1992 Apr 3;69(1):185-95
pubmed: 1555239
Pharmacol Ther. 2007 Jan;113(1):50-87
pubmed: 17005254
PLoS One. 2012;7(8):e41446
pubmed: 22916108
Cell Rep. 2018 Sep 18;24(12):3339-3352
pubmed: 30232013
Cell Mol Life Sci. 2019 Aug;76(15):2933-2956
pubmed: 31101937
Oncotarget. 2017 Apr 24;8(42):71685-71698
pubmed: 29069738
Proc Natl Acad Sci U S A. 2013 Sep 10;110(37):14894-9
pubmed: 23980157
Nucleic Acids Res. 2018 Jan 4;46(D1):D794-D801
pubmed: 29126249
J Med Chem. 2020 May 28;63(10):5477-5487
pubmed: 32367723
Genes Dev. 2007 Dec 15;21(24):3369-80
pubmed: 18079182
Cancer Sci. 2015 Jun;106(6):665-71
pubmed: 25788321
Nature. 2012 Sep 6;489(7414):57-74
pubmed: 22955616
J Biol Chem. 2004 Nov 19;279(47):49281-8
pubmed: 15377655
Nucleic Acids Res. 2010 Apr;38(7):2201-16
pubmed: 20047962
Int J Biochem Cell Biol. 2012 Dec;44(12):2333-41
pubmed: 23032699
Nature. 1999 Apr 1;398(6726):422-6
pubmed: 10201372
PLoS One. 2016 Feb 05;11(2):e0148892
pubmed: 26848759
PLoS Genet. 2016 Mar 18;12(3):e1005946
pubmed: 26990877
Endocr Relat Cancer. 2012 Jul 22;19(4):509-26
pubmed: 22673335
Nucleic Acids Res. 2019 Jan 8;47(D1):D607-D613
pubmed: 30476243
Cancers (Basel). 2016 Jul 20;8(7):
pubmed: 27447672
Am J Cancer Res. 2018 Jun 01;8(6):932-943
pubmed: 30034932
Curr Opin Biotechnol. 2008 Aug;19(4):331-7
pubmed: 18590817
Oncotarget. 2017 Dec 27;9(10):9010-9020
pubmed: 29507670
Haematologica. 2018 Jan;103(1):18-29
pubmed: 29025910
Blood. 2015 Jun 4;125(23):3570-9
pubmed: 25911237
EMBO J. 2012 Jun 13;31(12):2714-36
pubmed: 22617422
Biochim Biophys Acta. 2014 Sep;1843(9):2067-78
pubmed: 24742914
Crit Rev Eukaryot Gene Expr. 2013;23(3):265-74
pubmed: 23879542
Nature. 1996 Aug 15;382(6592):638-42
pubmed: 8757136
Proc Natl Acad Sci U S A. 2003 Jun 24;100(13):7480-5
pubmed: 12802011
Nat Rev Cancer. 2011 Jul 07;11(8):558-72
pubmed: 21734724
Biosci Rep. 2009 Apr;29(2):131-41
pubmed: 19220199
Int J Cancer. 2011 Feb 1;128(3):562-73
pubmed: 20473859

Auteurs

Lucas Schneider (L)

Goethe University, Institute for Transfusion Medicine and Immunohematology, and German Red Cross Blood Service BaWüHe, Institute Frankfurt, Frankfurt, Germany.

Stefanie Herkt (S)

Goethe University, Institute for Transfusion Medicine and Immunohematology, and German Red Cross Blood Service BaWüHe, Institute Frankfurt, Frankfurt, Germany.

Lei Wang (L)

Department of Eukaryotic Genetics, Institute of Industrial Genetics, University of Stuttgart, Stuttgart, Germany.

Christine Feld (C)

Department of Eukaryotic Genetics, Institute of Industrial Genetics, University of Stuttgart, Stuttgart, Germany.

Josephine Wesely (J)

Georg-Speyer-Haus, Institute for Tumor Biology and Experimental Therapy, Frankfurt am Main, Germany.
Automated Systems and Genomics, The New York Stem Cell Foundation Research Institute, New York, USA.

Olga N Kuvardina (ON)

Goethe University, Institute for Transfusion Medicine and Immunohematology, and German Red Cross Blood Service BaWüHe, Institute Frankfurt, Frankfurt, Germany.

Annekarin Meyer (A)

Goethe University, Institute for Transfusion Medicine and Immunohematology, and German Red Cross Blood Service BaWüHe, Institute Frankfurt, Frankfurt, Germany.

Thomas Oellerich (T)

Department of Medicine II, Hematology/Oncology, Goethe University, Frankfurt, Germany.
German Cancer Research Center and German Cancer Consortium, Heidelberg, Germany.
Department of Molecular Diagnostics/Translational Proteomics, Frankfurt Cancer Institute, Frankfurt, Germany.

Björn Häupl (B)

Department of Medicine II, Hematology/Oncology, Goethe University, Frankfurt, Germany.
German Cancer Research Center and German Cancer Consortium, Heidelberg, Germany.
Department of Molecular Diagnostics/Translational Proteomics, Frankfurt Cancer Institute, Frankfurt, Germany.

Erhard Seifried (E)

Goethe University, Institute for Transfusion Medicine and Immunohematology, and German Red Cross Blood Service BaWüHe, Institute Frankfurt, Frankfurt, Germany.

Halvard Bonig (H)

Goethe University, Institute for Transfusion Medicine and Immunohematology, and German Red Cross Blood Service BaWüHe, Institute Frankfurt, Frankfurt, Germany.
Department of Medicine, Division of Hematology, University of Washington, Seattle, WA, USA.

Joern Lausen (J)

Department of Eukaryotic Genetics, Institute of Industrial Genetics, University of Stuttgart, Stuttgart, Germany. joern.lausen@iig.uni-stuttgart.de.

Classifications MeSH